Hemostemix Joins The OTCQX Marketplace In The United States

TORONTO, ONTARIO--(Marketwired - Dec 28, 2015) - Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM)(OTCQX:HMTXF), a clinical-stage autologous cell-therapy company, announced today that it has been approved for and commenced trading on the OTCQX marketplace under the symbol “HMTXF.” Hemostemix will continue to trade on the TSX Venture Exchange under the symbol “HEM.”

OTCQX is the top tier of the three marketplaces for trading over-the-counter stocks provided and operated by the OTC Markets Group. To qualify for the OTCQX marketplace, companies must meet high financial standards, demonstrate compliance with U.S. securities laws, be current in their disclosure, and be sponsored by a professional third-party advisor.

Trading on OTCQX enables U.S. investors to trade their ordinary shares in U.S. dollars and provides convenient access to the Company’s news and financial disclosures. Investors can find current financial disclosures and Real-Time Level 2 quotes for Hemostemix at otcmarkets.com.

“Joining OTCQX expands the marketplace for Hemostemix shares and broadens the Company’s access to both current and prospective U.S. shareholders,” said Dr. Elmar Burchardt, Hemostemix president and CEO. “We are excited to offer our U.S. shareholders and followers an opportunity to invest directly.”

Hemostemix has retained ROTH Capital Partners, LLC to serve as its Principal American Liaison (PAL), responsible for providing guidance on OTCQX requirements and U.S. securities laws.

About Hemostemix

Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, phase-2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase-2 trial targets a participant’s diseased tissue with proprietary cells that are grown from his or her blood and capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada.

For more information, visit hemostemix.com or email office@hemostemix.com.

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.